The overall objective of this study is to compare the overall pattern of \[18F\]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
230
In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Assessment of [18F]APN-1607 Uptake Patterns by Regional SUVR Values
Regional \[18F\]APN-1607 uptake patterns will be assessed in regions of interest (ROIs) and an iROI that are relevant to AD pathology. \[18F\]APN-1607 uptake patterns identified by regional analysis will be compared among healthy subjects, subjects with MDAD, and subjects with AD dementia. Standard uptake value (SUV) will be calculated for each ROI, and SUVRs will be calculated by normalizing SUV of ROIs to the SUV of relevant reference region.
Time frame: 15 months
Safety and Tolerability Profile Measured by Adverse Events (AEs)
Safety and tolerability profile for the administration of \[18F\]APN-1607 and positron emission tomography (PET) scanning are measured by number of participants with adverse events (AEs).
Time frame: 15 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.